Accueil・Liste d'Actions・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Fermé

SecteurSoins de santé

58.79 1.75

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

58.41

Max

58.99

Chiffres clés
By Trading Economics
Revenu	-34M 106M
Ventes	-108M 766M
P/E Moyenne du Secteur	41.234 56.269
BPA	0.76
Marge bénéficiaire	13.773
Employés	3,221
EBITDA	177M 173M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+47.48% upside

Dividendes
By Acuity
Prochains Résultats	3 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	679M 11B
Ouverture précédente	57.04
Clôture précédente	58.79

Sentiment de l'Actualité

By Acuity

34%

66%

89 / 342 Classement par Healthcare

BioMarin Pharmaceutical Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juil. 2026, 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

1 juil. 2026, 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

30 juin 2026, 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

29 juin 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, retracing from earlier gains amid mixed U.S. equity performance and broader inflation concerns.

26 juin 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

25 juin 2026, 23:31 UTC

Biomarin Pharmaceutical shares declined in after-market trading, despite remaining above the 20-day moving average and near the upper end of its one-month range.

24 juin 2026, 19:41 UTC

Biomarin Pharmaceutical Inc is gaining Wednesday, supported by strong momentum in the Biotechnology sub-sector, despite an earlier decline in the session.

23 juin 2026, 23:56 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. Broader market sentiment is affected by declines in Asian markets amid tech sector concerns.

22 juin 2026, 23:56 UTC

Biomarin Pharmaceutical shares showed little change in after-market trading. The stock remains within the middle of its one-month trading range.

19 juin 2026, 00:01 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market hours, recovering from earlier lows and reflecting strong performance since Thursday's close.

18 juin 2026, 23:21 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close despite earlier fluctuations in the session.

17 juin 2026, 20:08 UTC

Event

Biomarin Pharmaceutical is trading lower amid broader market declines, despite presenting new data on VOXZOGO® and BMN 333 at the ENDO 2026 conference.

16 juin 2026, 23:41 UTC

Event

Biomarin Pharmaceutical presented new data on investigational therapies at the Endocrine Society Annual Meeting. Shares showed little change during after-market hours.

15 juin 2026, 13:26 UTC

Biomarin Pharmaceutical Inc is trading higher in pre-market hours, reflecting positive momentum amid a broader upward trend in Asian markets, including a surge in the Nikkei Index.

13 juin 2026, 00:01 UTC

Biomarin Pharmaceutical Inc shares declined in after-market trading, retracing from earlier gains while remaining above the 20-day moving average. No specific news was identified.

12 juin 2026, 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

11 juin 2026, 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, reaching an early session low. Broader economic news includes an unexpected rise in initial jobless claims.

10 juin 2026, 20:03 UTC

Biomarin Pharmaceutical shares are lower today, reflecting broader market trends amid volatility. The stock peaked earlier in the session before declining significantly.

9 juin 2026, 20:03 UTC

Biomarin Pharmaceutical Inc shares are higher, reaching a session high and trading above its 20-day moving average. No specific news was identified for the move.

8 juin 2026, 22:51 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, reflecting a notable decline despite a broader rebound in US stocks, particularly in the semiconductor sector.

5 juin 2026, 20:07 UTC

Biomarin Pharmaceutical Inc shares are modestly higher, reflecting broader market gains amid robust job growth data. No specific company news was identified.

4 juin 2026, 22:31 UTC

Biomarin Pharmaceutical Inc is trading lower in after-market hours amid a broader market decline and rising U.S. Treasury yields impacting biotechnology stocks.

3 juin 2026, 20:06 UTC

Biomarin Pharmaceutical shares are higher amid broader market strength following a positive ADP Employment Report, which showed job growth exceeding expectations.

2 juin 2026, 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, continuing a decline since Monday. The stock closed at its lowest point after an early high.

1 juin 2026, 23:03 UTC

Biomarin Pharmaceutical shares declined in after-market trading, continuing a downward trend since Monday's close, despite remaining above the 20-day moving average.

29 mai 2026, 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid routine trading patterns.

28 mai 2026, 22:36 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting notable movement since Thursday's close amid broader market dynamics and economic data.

27 mai 2026, 19:41 UTC

Biomarin Pharmaceutical Inc shares are lower Wednesday, reversing recent gains. No specific news was identified to explain the decline since Tuesday's close.

26 mai 2026, 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from a recent trend of higher closes amid rising bond yields and no specific company news.

Comparaison

Variation de prix

BioMarin Pharmaceutical Inc prévision

Objectif de Prix

By TipRanks

47.48% hausse

Prévisions sur 12 Mois

Moyen 87 USD 47.48%

Haut 120 USD

Bas 50 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

20 ratings

Achat

Maintien

Vente

Basé sur 20 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

89 / 342Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.